PRT 2761

Drug Profile

PRT 2761

Alternative Names: PRT; PRT2761

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Ora Inc
  • Class Eye disorder therapies
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis

Most Recent Events

  • 13 Oct 2017 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT03320434)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top